SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 28, 2003
----------------------
COMMISSION FILE NUMBER 1-12584
DELAWARE SHEFFIELD PHARMACEUTICALS, INC. 13-3808303
(State of other jurisdiction of (Exact name of registrant as specified (I.R.S. Employer
incorporation or organization) in its charter) Identification No.)
3136 Winton Road South, Suite 201, Rochester, New York 14623
------------------------------------------------------ -----
(Address of principal executive officers) (Zip Code)
Registrant's telephone number, including area code (585) 292-0310
----------------------
14528 South Outer Forty Road, Suite 205, St. Louis, Missouri 63017
------------------------------------------------------ -----
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS
On January 24, 2003, Sheffield Pharmaceuticals, Inc., a Delaware
corporation, issued a press release, a copy of which is attached hereto as
Exhibit 99.3 and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
Exhibit Number Description
99.3 Press Release dated January 24, 2003 issued by Sheffield
Pharmaceuticals, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
SHEFFIELD PHARMACEUTICALS, INC.
Dated: January 28, 2003 By: /s/ Scott A. Hoffmann
-------------------------------------
Scott A. Hoffmann
Vice President and Chief Financial Officer